Skip to main content
Clinical Trials/NCT00835848
NCT00835848
Completed
Phase 4

Pharmacological Postconditioning to Reduce Infarct Size Following Primary PCI in Patients With STEMI

Rigshospitalet, Denmark1 site in 1 country100 target enrollmentJanuary 2009

Overview

Phase
Phase 4
Intervention
Exenatide
Conditions
Myocardial Infarction
Sponsor
Rigshospitalet, Denmark
Enrollment
100
Locations
1
Primary Endpoint
Infarct size by MRI
Status
Completed
Last Updated
11 years ago

Overview

Brief Summary

Both pre- and postconditioning seem to protect cardiomyocytes during reperfusion therapy. Investigations both ex vivo and in vivo suggest that a gut derived hormone, Glucagon-Like-Peptide-1 (GLP-1), is able to reduce reperfusioninjury after myocardial ischemia. Results from our own laboratory have shown a marked reduction in infarct size when rat hearts in a Langendorf preparation were exposed to the GLP-1 analogue, exendin-4. The investigators want to investigate to what extent this effect can be translated to humans in the setting of acute STEMI treated with primary PCI when evalutaed by cardiac magnetic resonance imaging.

Registry
clinicaltrials.gov
Start Date
January 2009
End Date
May 2015
Last Updated
11 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Thomas Engstrom

Chief consultant

Rigshospitalet, Denmark

Eligibility Criteria

Inclusion Criteria

  • More than 18 years of age.
  • STEMI less than 12 hours from onset of pain. STEMI defined as as ST-segment elevation in 2 contiguous electrocardiographic leads of \>0.1 mV in V4 - V6 or limb leads II, III and aVF, or \>0.2 mV in lead V1 - V
  • TIMI 0-1 in infarct related artery.
  • Oral and written informed consent.

Exclusion Criteria

  • Multivessel disease defined by one or more stenoses \>70% in diameter in the non infarct related artery.
  • Previous myocardial infarction.
  • Stent trombosis.
  • Previous CABG.
  • Less than TIMI 2 following wiring and predilatation of the infarct related artery but prior to postconditioning or placebo treatment.
  • Renal insufficiency (creatinin \>200).
  • Pregnancy or lactation.
  • Diabetic ketoacidose eller hypoglycemia (plasma glukose \< 2.5 mmol/l).
  • Pancreatitis.

Arms & Interventions

Exenatide

25 μg Byetta (Lilly, Exenatide) is added to 250 ml isotonic NaCl. Infusion is started immediately at 72ml/hour for 15 min, followed by 26ml/hour to be contoinued for 6 hours.

Intervention: Exenatide

Saline

Isotonic saline infusion is started immediately at 72ml/hour for 15 min, followed by 26ml/hour to be contoinued for 6 hours.

Intervention: Saline

Outcomes

Primary Outcomes

Infarct size by MRI

Time Frame: 3 months

Secondary Outcomes

  • Cardiel death after 1 and 15 months.(15 months)

Study Sites (1)

Loading locations...

Similar Trials